IND Swift Limited — Ramipril Exporter Profile
Indian Pharmaceutical Exporter · #5 for Ramipril · $7.6M export value · DGFT Verified
IND Swift Limited is the #5 Indian exporter of Ramipril with $7.6M in export value and 307 verified shipments. IND Swift Limited holds a 7.1% market share in Ramipril exports across 3 countries. The company exports 13 pharmaceutical products worth $36.7M across 9 therapeutic categories.
IND Swift Limited — Ramipril Export Profile: Buyers & Destinations
Where Does IND Swift Limited Export Ramipril?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED KINGDOM | $4.2M | 234 | 81.6% |
| AUSTRALIA | $935.7K | 71 | 18.3% |
| UNITED ARAB EMIRATES | $6.2K | 2 | 0.1% |
IND Swift Limited exports Ramipril to 3 countries. The largest destination is UNITED KINGDOM accounting for 81.6% of IND Swift Limited's Ramipril shipments, followed by AUSTRALIA (18.3%) and UNITED ARAB EMIRATES (0.1%). These destinations reflect IND Swift Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ramipril from IND Swift Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| WOCKHARDT UK LIMITED | UNITED KINGDOM | $4.2M | 234 |
| ARROW PHARMACEUTICALS PTY LTD. | AUSTRALIA | $369.5K | 30 |
| ARROW PHARMACEUTICALS PTY LTD | AUSTRALIA | $325.2K | 21 |
| APOTEX PTY LTD | AUSTRALIA | $128.0K | 8 |
| HEALTHCARE LOGISTICS | AUSTRALIA | $38.5K | 2 |
| ARROW PHARMACEUTICALS PTY LIMITED | AUSTRALIA | $26.6K | 8 |
| APOTEX PTY LIMITED | AUSTRALIA | $24.0K | 1 |
| APOTEX PTY LTD. | AUSTRALIA | $23.8K | 1 |
| BIOVENTURE HEALTHCARE FZE | UNITED ARAB EMIRATES | $6.2K | 2 |
IND Swift Limited supplies Ramipril to 9 buyers globally. The largest buyer is WOCKHARDT UK LIMITED (UNITED KINGDOM), followed by ARROW PHARMACEUTICALS PTY LTD. (AUSTRALIA) and ARROW PHARMACEUTICALS PTY LTD (AUSTRALIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ramipril Export Value and How Much Does IND Swift Limited Contribute?
India exported $82.5M worth of Ramipril through 4,977 shipments from 177 suppliers to 93 countries, serving 389 buyers globally. IND Swift Limited contributes $7.6M to this total, accounting for 7.1% of India's Ramipril exports. IND Swift Limited ships Ramipril to 3 countries through 9 buyers.
What Is the Average Shipment Value for IND Swift Limited's Ramipril Exports?
IND Swift Limited's average Ramipril shipment value is $24.6K per consignment, based on 307 shipments totaling $7.6M. The largest destination is UNITED KINGDOM (81.6% of IND Swift Limited's Ramipril exports).
How Does IND Swift Limited Compare to Other Indian Ramipril Exporters?
IND Swift Limited ranks #5 among 177 Indian Ramipril exporters with a 7.1% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($16.0M), GENO PHARMACEUTICALS PRIVATE LIMITED ($14.0M), AUROBINDO PHARMA LTD ($13.3M). IND Swift Limited processed 307 shipments to 3 destination countries.
What Ramipril Formulations Does IND Swift Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| RAMIPRIL 1.25 MG CAPSULES(RAMIPRIL 1.25 | $103.4K | 5 |
| RAMIPRIL 2.5 MG CAPSULES(RAMIPRIL 2.5 MG | $60.7K | 3 |
| RAMIPRIL 10 MG CAPSULES (RAMIPRIL 10 MG)B.NO.AEC11224 TO AEC11424 MFG.FEB-2024,EXP.JAN-2027 (120410X28=3371480 NOS)NOS | $58.6K | 3 |
| RAMIPRIL 10 MG CAPSULES (RAMIPRIL 10 MG)B.NO.AEC12924,AEC13024,AEC13124 MFG.APR-2024,EXP.MAR-2027(120570X28=3375960 NOS) | $56.2K | 3 |
| RAMIPRIL 10 MG CAPSULES(RAMIPRIL 10 MG CAPS.)B.NO.AEC13224 TO AEC13424 MFG.APR-2024,EXP.MAR-2027(119770X28=3353560 NOS) | $55.8K | 3 |
| RAMIPRIL 5 MG CAPSULES(RAMIPRIL 5MG)BATCH NO.AEB10324 TO AEB10524 MFG.JAN-2024,EXP.DEC-2026 (119770X28=3353560 NOS)NOS | $50.1K | 3 |
| PRILACE 10 MG(Ramipril 10mg capsules),BT | $50.0K | 1 |
| RAMIPRIL 10 MG CAPSULES B.NO.AEC10623 TO | $50.0K | 1 |
| RAMIPRIL 10MG CAPSULES BATCH NO.AEC10923 | $50.0K | 1 |
| RAMIPRIL 10 MG BATCH NO.AEC11623,AEC1172 | $50.0K | 1 |
IND Swift Limited exports 188 distinct Ramipril formulations including tablets, capsules, syrups, and combination drugs. The top formulation is RAMIPRIL 1.25 MG CAPSULES(RAMIPRIL 1.25 with 5 shipments worth $103.4K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Ramipril to Key Markets
What IND Swift Limited must comply with to export Ramipril to its top destination countries
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does IND Swift Limited Compare to Nearest Ramipril Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | GENO PHARMACEUTICALS PRIVATE LIMITED | $14.0M | 686 | 1 | $20.5K |
| 3 | AUROBINDO PHARMA LTD | $13.3M | 811 | 8 | $16.4K |
| 5 | IND SWIFT LIMITED ★ | $6.4M | 307 | 3 | $20.8K |
| 6 | ZENTIVA PRIVATE LIMITED | $4.9M | 233 | 5 | $21.0K |
| 7 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $4.8M | 361 | 5 | $13.2K |
IND Swift Limited ranks #5 among 177 Indian Ramipril exporters. Average shipment value of $20.8K compared to the market average of $466.2K. The closest competitors by value are GENO PHARMACEUTICALS PRIVATE LIMITED and AUROBINDO PHARMA LTD.
Which Indian Ports Ship Ramipril Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 658 | 13.2% |
| JNPT/ NHAVA SHEVA SEA | 553 | 11.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 305 | 6.1% |
| SAHAR AIR | 291 | 5.8% |
| JNPT | 271 | 5.4% |
| DELHI AIR CARGO ACC (INDEL4) | 214 | 4.3% |
| DELHI AIR | 201 | 4.0% |
| VIZAG SEA | 194 | 3.9% |
What Other Cardiovascular Products Does IND Swift Limited Export?
IND Swift Limited also exports these cardiovascular products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on IND Swift Limited's Ramipril Exports
Ind-Swift Laboratories' export operations have been influenced by recent geopolitical developments. The Israel-Iran conflict has heightened security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and increased freight rates by 40–50% on key India–Europe routes, impacting the company's logistics and cost structures. (livemint.com)
Conversely, the India–European Union Free Trade Agreement (India–EU FTA), concluded in January 2026, is poised to benefit Indian pharmaceutical exporters. The agreement eliminates tariffs on most European pharmaceutical imports, enhancing the competitiveness of Indian products in the EU market. This development presents an opportunity for Ind-Swift Laboratories to expand its footprint in Europe. (en.wikipedia.org)
In the United States, the reshoring of pharmaceutical manufacturing and potential imposition of tariffs on imports pose challenges for Indian exporters. While there are currently no import duties on Indian pharmaceutical products entering the US, the introduction of tariffs could affect the profitability of low-margin generic drugs, potentially leading to market exits. (cfo.economictimes.indiatimes.com)
IND Swift Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains paramount for Indian pharmaceutical exporters. Ind-Swift Laboratories has demonstrated a commitment to quality by adhering to Good Manufacturing Practices (GMP) as stipulated by the US FDA, WHO, and EU authorities. The company's manufacturing facilities in Punjab and Jammu have been inspected and approved by these regulatory bodies, facilitating access to regulated markets.
The evolving regulatory landscape, including the EU's Falsified Medicines Directive, necessitates continuous investment in quality systems and supply chain transparency. Ind-Swift Laboratories' focus on high-margin formulations underscores the importance of maintaining stringent quality standards to meet global regulatory requirements and sustain market access.
About IND Swift Limited
IND Swift Limited exports 13 products worth $36.7M. Beyond Ramipril, top products include Fexofenadine, Clarithromycin, Loratadine, Ezetimibe, Terbinafine. View the complete IND Swift Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ramipril — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ramipril shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: IND Swift Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 307 individual customs records matching IND Swift Limited exporting Ramipril, covering 188 formulations to 3 countries via 9 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 93+ countries, 389+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ramipril Export Data from IND Swift Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for IND Swift Limited's Ramipril exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
IND Swift Limited
Full Company Profile →
13 products · $36.7M total trade · 9 categories
Ramipril Stats
Company Overview
Top Products by IND Swift Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for IND Swift Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ramipril. For current shipment-level data, contact TransData Nexus.